Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22591639 | 0.85 | TAAR1 (0.69) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL5872238 | 0.82 | ADRA2A (0.58) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL1168170 | 0.82 | ADRA2A (0.58) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL15667190 | 0.82 | ADRA2A (0.58) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL27842768 | 0.81 | TAAR1 (0.64) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 0.80 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL8859 | 0.80 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL15094242 | 0.80 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL910141 | 0.80 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL9673275 | 0.80 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | TAAR1 2595/4885SLC6A2 1618/4885SLC6A4 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.